| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5378804 | MERCK | Aza cyclohexapeptide compounds |
Mar, 2013
(11 years ago) | |
| US5792746 | MERCK | Aza cyclohexapeptide compounds |
Mar, 2013
(11 years ago) | |
|
US5378804 (Pediatric) | MERCK | Aza cyclohexapeptide compounds |
Sep, 2013
(10 years ago) | |
|
US5792746 (Pediatric) | MERCK | Aza cyclohexapeptide compounds |
Sep, 2013
(10 years ago) | |
| US5514650 | MERCK | Aza cyclohexapeptide compounds |
Jan, 2015
(9 years ago) | |
|
US5514650 (Pediatric) | MERCK | Aza cyclohexapeptide compounds |
Jul, 2015
(8 years ago) | |
| US6136783 | MERCK | Antifungal compositions |
Mar, 2017
(7 years ago) | |
| US5952300 | MERCK | Antifungal compositions |
Mar, 2017
(7 years ago) | |
|
US6136783 (Pediatric) | MERCK | Antifungal compositions |
Sep, 2017
(6 years ago) | |
|
US5952300 (Pediatric) | MERCK | Antifungal compositions |
Sep, 2017
(6 years ago) | |
Cancidas is owned by Merck.
Cancidas contains Caspofungin Acetate.
Cancidas has a total of 10 drug patents out of which 10 drug patents have expired.
Expired drug patents of Cancidas are:
- US5378804
- US5792746
- US5378804*PED
- US5792746*PED
- US5514650
- US5514650*PED
- US6136783
- US5952300
- US6136783*PED
- US5952300*PED
Cancidas was authorised for market use on 26 January, 2001.
Cancidas is available in powder;intravenous dosage forms.
Cancidas can be used as cancidas is indicated for empirical therapy for presumed fungal infections in febrile, neutropenic patients..
The generics of Cancidas are possible to be released after 28 September, 2017.
Drugs and Companies using CASPOFUNGIN ACETATE ingredient
Market Authorisation Date: 26 January, 2001
Treatment: Cancidas is indicated for empirical therapy for presumed fungal infections in febrile, neutropenic patients.
Dosage: POWDER;INTRAVENOUS
CANCIDAS family patents
